Trial Profile
An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TREASURE
- Sponsors Astellas Pharma
- 27 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 08 Jul 2013 Planned End Date changed from 1 May 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 25 Jan 2012 New trial record